跳至主要内容
临床试验/CTRI/2013/02/003360
CTRI/2013/02/003360招募中4 期

Efficacy of intravenous â??L-ornithine L-aspartateâ?? in reversal of overt acute hepatic encephalopathy in patients with liver cirrhosis: a prospective, randomized, double-blind, placebo controlled trial - HEAL (Hepatic Encephalopathy and LOLA)

Department of Gastroenterology0 个研究点目标入组 164 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中
入组人数
164

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • a. Hepatic cirrhosis based on clinical, biochemical, radiological and/or histological data.
  • b. Patients with overt acute grade 2, 3 and 4 HE, according to the West Haven criteria.
  • c. Age of patient >18 years
  • d. Patients with or without a precipitating factor for the HE.

排除标准

  • a.Patients who are terminally ill (End Stage Liver Disease, MELD more than 15)
  • b.Chronic HE, on Lactulose or antibiotics
  • c.Acute superposed liver injury (hepatitis) or acute on chronic liver failure
  • d.Severe septicemia with shock
  • e.Hepatocellular carcinoma
  • f. Wilsonâ??s disease as the etiological factor of liver disease
  • g. Advanced cardiac or pulmonary disease
  • h.Acute renal failure or end stage renal disease
  • i.Neuro-degenerative disease or major psychiatric illness
  • j.Patients on sedatives or antidepressants
  • k.Pregnancy or breastfeeding

研究者

相似试验